GlassScriptPhysician profile
Khai T Vu
NPI 1316912199
$1,015.61
in general payments reported to CMS, 2019-2025
16 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $52.71 · 2021: $14.89 · 2022: $30.80 · 2023: $303 · 2024: $132 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $224.75 | 2019-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $122.41 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Amgen INC. | $109.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $100.32 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $71.39 | 2019-2021 | |
| Sanofi Pasteur INC. | $58.03 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.18 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.81 | 2019-2023 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $49.49 | 2023-2024 | Orgovyx |
| Merck Sharp & Dohme LLC | $42.60 | 2023-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Lilly USA, LLC | $42.07 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $28.90 | 2025 | |
| Telix Pharmaceuticals | $20.86 | 2023 | Illuccix |
| Exact Sciences Corporation | $16.26 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $14.46 | 2023 | Heplisav-B |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.08 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khai Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.